Serological Analysis and Drug Resistance of Chlamydia pneumoniae and Mycoplasma pneumoniae in 4500 Healthy Subjects in Shenzhen, China

Abstract

Objective To understand the prevalence and distribution of Chlamydia pneumoniae (CP) and Mycoplasma pneumoniae (MP) in the population and to provide a basis for the prevention and treatment of respiratory tract infection. Methods This study included a total of 4500 healthy subjects who were given physical examination in Shenzhen People's Hospital from January to December in 2016. Venous blood was drawn from people to detect the MP- and CP-specific IgG and IgM in the serum using chemiluminescence immunoassay (CLIA). The relationship of MP and CP infections with patient age, seasons, and percentage of infections was analyzed. Conclusion CP and MP cause high rate of asymptomatic infection, which may be associated with the high incidence of CP and MP infection, especially in children and the elderly population. Therefore, the implementation of effective and practical prevention measures has become an urgent need. MP culture and drug sensitivity test should be performed as early as possible in patients with manifested MP infections in order to ensure timely and proper treatment and to reduce the emergence of drug-resistant strains.

Comparative efficacy of Chinese herbal injections combined with azithromycin for mycoplasma pneumonia in children: A Bayesian network meta‐analysis of randomized controlled trials

“…Azithromycin, a broad‐spectrum antibacterial and second‐generation macrolide, could inhibit bacterial protein synthesis, quorum sensing and reduces the formation of biofilm . It has longer half‐life and cellular targeting, and is used to reduce respiratory and other bacterial infections, such as gram‐positive, gram‐negative and atypical bacterial infections that lead to pneumonia . Azithromycin is a first‐line outpatient treatment in the case of bacterial pneumonia in the United States, or as part of a combination therapy in patients who require hospitalization .…”

“…36 It has longer half-life and cellular targeting, and is used to reduce respiratory and other bacterial infections, such as gram-positive, gram-negative and atypical bacterial infections that lead to pneumonia. 10,35,37 Azithromycin is a first-line outpatient treatment in the case of bacterial pneumonia in the United…”

“…Due to the serious side effects of tetracycline and fluoroquinolones on children, macrolides have become first choice for the treatment of mycoplasma pneumonia in children . Azithromycin, a macrolide antibiotic, is a preferred decision because of its long half‐life and clear target‐cell effect . However, macrolide resistance has emerged worldwide with a significant increase, which increasingly lead to complex clinical treatment schemes .…”

“…3,9 Azithromycin, a macrolide antibiotic, is a preferred decision because of its long half-life and clear target-cell effect. 10 However, macrolide resistance has emerged worldwide with a significant increase, which increasingly lead to complex clinical treatment schemes. 2,[11][12][13][14][15] In recent years, with the increase of people' recognition of traditional Chinese medicine, combining Chinese Medicine and Western Medicine to treat diseases has been an acceptable treatment method.…”

Epidemiology and Molecular Identification of Mycoplasma pneumoniae associated respiratory tract, Zhejiang province, China, 2008-2017

“…The positive detection rate of MP varies greatly among different countries and regions, different populations and ages, different years and seasons [1,19,20] . In order to grasp the epidemic situation of indicates that MP infection is mainly concentrated in the age group below 18, suggesting that clinical attention should be paid to the early diagnosis and prevention of MP infection in adolescents.…”